Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital

Rhea-AI Filing Summary

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of Stoke Therapeutics, Inc. common stock. They report an aggregate 4,038,404 shares of common stock, representing 6.5% of the class, based on 62,240,347 shares outstanding as of March 31, 2026.

The Reporting Persons have no sole voting or dispositive power over these shares and instead report shared voting and shared dispositive power over all 4,038,404 shares. The shares are held by Lynx1 Master Fund LP and a managed account, and the Lynx1 Fund has the right to receive dividends and sale proceeds from the reported shares. The statement notes that the filing should not be construed as an admission that any Reporting Person is the beneficial owner for all purposes.

Key Figures

Shares beneficially owned: 4,038,404 shares Percent of class: 6.5% Shares outstanding baseline: 62,240,347 shares +2 more

5 metrics

Shares beneficially owned 4,038,404 shares Common stock of Stoke Therapeutics reported by the Reporting Persons

Percent of class 6.5% Ownership percentage of Stoke Therapeutics common stock

Shares outstanding baseline 62,240,347 shares Stoke Therapeutics common stock outstanding as of March 31, 2026

Shared voting power 4,038,404 shares Shares over which Reporting Persons share voting power

Shared dispositive power 4,038,404 shares Shares over which Reporting Persons share dispositive power

Key Terms

beneficial owner, shared voting power, shared dispositive power, percent of class, +1 more

5 terms

beneficial owner regulatory

"not be construed as an admission that any Reporting Person is, for the purposes of Section 13, the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared voting power regulatory

"Shared Voting Power 4,038,404.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power regulatory

"Shared Dispositive Power 4,038,404.00"

percent of class financial

"Percent of class: 6.5%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Schedule 13G regulatory

"for the purposes of Section 13 of the Securities Exchange Act of 1934"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What stake in Stoke Therapeutics (STOK) does Lynx1 Capital report?

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 4,038,404 shares of Stoke Therapeutics common stock, representing 6.5% of the outstanding class, based on 62,240,347 shares reported outstanding as of March 31, 2026.

How much voting power over STOK shares does Lynx1 Capital have?

The Reporting Persons disclose 0 shares with sole voting power and 4,038,404 shares with shared voting power. All 4,038,404 reported shares are subject to shared voting authority rather than individual control.

Who actually receives dividends and sale proceeds from the STOK shares?

The filing states that Lynx1 Master Fund LP has the right to receive, or direct the receipt of, dividends and sale proceeds from the 4,038,404 shares of Stoke Therapeutics common stock reported as beneficially owned.

How is the 6.5% ownership in Stoke Therapeutics (STOK) calculated?

The reported 6.5% interest is calculated using 62,240,347 shares of Stoke Therapeutics common stock outstanding as of March 31, 2026, as referenced from a company Form 8-K exhibit.

Do Lynx1 Capital and Weston Nichols claim sole dispositive power over STOK?

No. They report 0 shares with sole dispositive power and 4,038,404 shares with shared dispositive power. This means decisions to sell or otherwise dispose of the shares are subject to shared, not individual, authority.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:38 PM Accepted by SEC EDGAR 08/14/2026 - 04:33 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Stoke Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

86150R107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 86150R107

1

Names of Reporting Persons

Lynx1 Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,038,404.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,038,404.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,038,404.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 86150R107

1

Names of Reporting Persons

Weston Nichols

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,038,404.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,038,404.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,038,404.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Stoke Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 45 Wiggins Ave, Bedford, Massachusetts 01730.
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund") and a managed account, with respect to the common stock par value $0.0001 per share ("Common Stock"), of Stoke Therapeutics, Inc., a Delaware corporation (the "Company"), directly held by the Lynx1 Fund and the managed account; and (ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the Common Stock directly held by the Lynx1 Fund and the managed account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Weston Nichols c/o Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051
(c)	Citizenship: Investment Manager - Delaware Mr. Nichols - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 86150R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported in Exhibit 99.1 of the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 7, 2026.
(b)	Percent of class: 6.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lynx1 Capital Management LP

Signature:	/s/ Weston Nichols
Name/Title:	By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
Date:	08/14/2026

Weston Nichols

Signature:	/s/ Weston Nichols
Name/Title:	Weston Nichols, Individually
Date:	08/14/2026